{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:25:42Z","timestamp":1790144742903,"version":"4.0.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To date, various treatments for cystoid macular edema (CME) in retinitis pigmentosa (RP) have been reported. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of current treatments for RP-CME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PubMed, Embase and the Cochrane library were searched from inception to August 2021.\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , WHO ICTRP and ISRCTN were also searched for relevant studies. Only studies published in English were included. The RoB 2 tool was used to evaluate the risk of bias of randomized controlled trials (RCTs), and the MINORS scale was used to assess the methodological quality of non-RCTs. Review manager (Revman) was used to pool the data. The primary outcomes included the change of central macular thickness (CMT) and best-corrected visual acuity (BCVA) from baseline. The secondary outcomes included fluorescein angiography (FA) leakage, rebound of CME and adverse effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-two studies were included in the current systematic review and 7 studies were used for meta-analysis. Treatments for RP-CME included oral and topical carbonic anhydrase inhibitors (CAIs), systematic and local steroids, anti-VEGF therapy, NSAIDS, grid LASER photocoagulation, subliminal micropulse LASER, vitrectomy, lutein supplement and oral minocycline. CAIs and local steroids were proved to be effective in reducing CMT. The effects of anti-VEGF reagents varied among studies. Regarding other treatments, only one study for each method fitted the inclusion criteria, so the evidence was very limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Topical CAIs, oral CAIs and local steroids are effective in treating RP-CME. However, due to the overall inferior design and small patient number of the included studies, the quality of evidence was poor. Systematic steroids, LASER, NSAIDS and vitrectomy may also be effective, nevertheless, considering the limited number of studies, no conclusion could be drawn regarding these treatments. More well-designed and conducted studies are needed in this field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021273979<\/jats:ext-link>\n                      , identifier CRD42021273979.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.895208","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T03:38:15Z","timestamp":1652672295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Management of Cystoid Macular Edema in Retinitis Pigmentosa: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Chen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/08820538.2016.1228404","article-title":"Comander J. Management of cystoid macular edema in retinitis pigmentosa","volume":"32","author":"Huckfeldt","year":"2017","journal-title":"Semin Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"750586","DOI":"10.3389\/fmed.2021.750586","article-title":"Gene therapy in inherited retinal diseases: an update on current state of the art","volume":"8","author":"Amato","year":"2021","journal-title":"Front Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/IAE.0b013e31809862aa","article-title":"Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial","volume":"28","author":"Adackapara","year":"2008","journal-title":"Retina."},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/bjophthalmol-2016-309376","article-title":"Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention","volume":"101","author":"Strong","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/archopht.1988.01060140350030","article-title":"Treatment of chronic macular edema with acetazolamide","volume":"106","author":"Cox","year":"1988","journal-title":"Arch Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0161-6420(94)31277-2","article-title":"Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa","volume":"101","author":"Fishman","year":"1994","journal-title":"Ophthalmology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/bjo.2006.107466","article-title":"Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa","volume":"91","author":"Fishman","year":"2007","journal-title":"Br J Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.survophthal.2017.09.009","article-title":"Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review","volume":"63","author":"Bakthavatchalam","year":"2018","journal-title":"Surv Ophthalmol."},{"key":"B9","first-page":"1","article-title":"Deflazacort treatment of cystoid macular edema in patients affected by retinitis pigmentosa: a pilot study","volume":"6","author":"Giusti","year":"2002","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10792-019-01228-z","article-title":"Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors","volume":"40","author":"Karasu","year":"2020","journal-title":"Int Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/IAE.0000000000001542","article-title":"Intravitreal dexamethasone implant in retinitis pigmentosa-related cystoid macular edema","volume":"38","author":"Mansour","year":"2018","journal-title":"Retina."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0186180","DOI":"10.1371\/journal.pone.0186180","article-title":"Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: a meta-analysis","volume":"12","author":"Huang","year":"2017","journal-title":"PLoS ONE."},{"key":"B13","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/IAE.0000000000002944","article-title":"Microstructural changes in cystoid macular edema in retinitis pigmentosa after intravitreal dexamethasone implant injection","volume":"41","author":"Park","year":"2021","journal-title":"Retina."},{"key":"B14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/jop.2018.0153","article-title":"dexamethasone implant produces better outcomes than oral acetazolamide in patients with cystoid macular edema secondary to retinitis pigmentosa","volume":"36","author":"Veritti","year":"2020","journal-title":"J Ocul Pharmacol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.oret.2020.05.012","article-title":"Effect of topical dorzolamide on cystoid macular edema in retinitis pigmentosa","volume":"4","author":"Shimokawa","year":"2020","journal-title":"Ophthalmol Retina."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/IAE.0000000000002589","article-title":"A randomized paired-eye trial of intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentos","volume":"40","author":"Park","year":"2020","journal-title":"Retina."},{"key":"B17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/bjophthalmol-2017-311392","article-title":"Retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors","volume":"103","author":"Strong","year":"2019","journal-title":"Br J Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1097\/IAE.0000000000003286","article-title":"Recurrence rate of cystoid macular edema with topical dorzolamide treatment and its risk factors in retinitis pigmentosa","volume":"62","author":"Shimokawa","year":"2021","journal-title":"Retina"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00417-017-3660-7","article-title":"Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study","volume":"255","author":"Sudhalkar","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1136\/bjophthalmol-2019-315152","article-title":"Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa","volume":"104","author":"Strong","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10103-020-03031-0","article-title":"Management of cystoid macular edema secondary to retinitis pigmentosa via subliminal micropulse yellow laser","volume":"36","author":"Arslan","year":"2021","journal-title":"Lasers Med Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0002-9394(14)74221-7","article-title":"Grid photocoagulation for macular edema in patients with retinitis pigmentosa","volume":"103","author":"Newsome","year":"1987","journal-title":"Am J Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/BF00919100","article-title":"Long-term treatment of retinitis pigmentosa with acetazolamide. A pilot study","volume":"231","author":"Orzalesi","year":"1993","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B27","first-page":"248","article-title":"Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa","volume-title":"Acta Ophthalmol Scand","author":"Ozdemir","year":"2005"},{"key":"B28","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/01.iae.0000250008.83779.23","article-title":"Optical coherence tomography in the diagnosis and monitoring of cystoid macular edema in patients with retinitis pigmentosa","volume":"26","author":"Chung","year":"2006","journal-title":"Retina"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1097\/IAE.0b013e31805f6b79","article-title":"Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa","volume":"27","author":"Apushkin","year":"2007","journal-title":"Retina."},{"key":"B30","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ajo.2005.12.030","article-title":"Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa","volume":"141","author":"Grover","year":"2006","journal-title":"Am J Ophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/archopht.125.6.759","article-title":"Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone","volume":"125","author":"Scorolli","year":"2007","journal-title":"Arch Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/jop.2009.0089","article-title":"Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa","volume":"25","author":"Artunay","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/02713680802710692","article-title":"Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa","volume":"34","author":"Yuzbasioglu","year":"2009","journal-title":"Curr Eye Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1001\/archophthalmol.2010.172","article-title":"Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome","volume":"128","author":"Genead","year":"2010","journal-title":"Arch Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1136\/bjophthalmol-2012-303005","article-title":"Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa","volume":"97","author":"Ikeda","year":"2013","journal-title":"Br J Ophthalmol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1167\/iovs.14-15995","article-title":"Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa","volume":"56","author":"Liew","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e000107","DOI":"10.1136\/bmjophth-2017-000107","article-title":"Efficacy of additional topical betamethasone in persistent cystoid macular oedema after carbonic anhydrase inhibitor treatments in retinitis pigmentosa","volume":"3","author":"Kitahata","year":"2018","journal-title":"BMJ Open Ophthalmol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/archopht.1989.01070020519031","article-title":"Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa","volume":"107","author":"Fishman","year":"1989","journal-title":"Arch Ophthalmol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00417-011-1904-5","article-title":"The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa","volume":"250","author":"Ikeda","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0161-6420(03)00259-8","article-title":"Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa","volume":"110","author":"Garc\u00eda-Arum\u00ed","year":"2003","journal-title":"Ophthalmology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000368052","article-title":"Comparison of topical dorzolamide and ketorolac treatment for cystoid macular edema in retinitis pigmentosa and usher's syndrome","volume":"233","author":"Reis","year":"2015","journal-title":"Ophthalmologica"},{"key":"B42","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s004170050175","article-title":"The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema","volume":"236","author":"Moldow","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/00006982-199705000-00009","article-title":"Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa","volume":"17","author":"Grover","year":"1997","journal-title":"Retina."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/archopht.1993.01090120062023","article-title":"Rebound of macular edema with continued use of methazolamide in patients with retinitis pigmentosa","volume":"111","author":"Fishman","year":"1993","journal-title":"Arch Ophthalmol."},{"key":"B45","first-page":"121","article-title":"Enhancement of retinal adhesion and subretinal fluid resorption by acetazolamide","volume":"23","author":"Marmor","year":"1982","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1001\/archopht.1986.01050230112043","article-title":"Pharmacologic modification of subretinal fluid absorption in the rabbit eye","volume":"104","author":"Marmor","year":"1986","journal-title":"Arch Ophthalmol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1517\/13543776.2012.707646","article-title":"Update on carbonic anhydrase inhibitors: a patent review (2008 - 2011)","volume":"22","author":"Aggarwal","year":"2012","journal-title":"Expert Opin Ther Pat."},{"key":"B48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2146\/ajhp170279","article-title":"Evaluating off-label uses of acetazolamide","volume":"75","author":"Van Berkel","year":"2018","journal-title":"Am J Health Syst Pharm."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/all.12881","article-title":"Drug allergies documented in electronic health records of a large healthcare system","volume":"71","author":"Zhou","year":"2016","journal-title":"Allergy."},{"key":"B50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1089\/ham.2010.1051","article-title":"Acetazolamide and sulfonamide allergy: a not so simple story","volume":"11","author":"Kelly","year":"2010","journal-title":"High Alt Med Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/0002-9394(88)90050-5","article-title":"Detection of lymphocytes in the vitreous gel of patients with retinitis pigmentosa","volume":"105","author":"Newsome","year":"1988","journal-title":"Am J Ophthalmol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ophtha.2012.07.006","article-title":"Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa","volume":"120","author":"Yoshida","year":"2013","journal-title":"Ophthalmology."},{"key":"B53","first-page":"200","article-title":"Investigations of antiretinal antibodies in pigmentary retinopathy and other retinal degenerations","author":"Heckenlively","year":"1996","journal-title":"Trans Am Ophthalmol Soc"},{"key":"B54","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jama.2019.8506","article-title":"Steroid side effects","volume":"322","author":"Grennan","year":"2019","journal-title":"JAMA"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2174\/1389450121666200428103334","article-title":"Anti-VEGF and retinal dystrophies","volume":"21","author":"Parodi","year":"2020","journal-title":"Curr Drug Targets"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1167\/iovs.07-1168","article-title":"Aqueous humor levels of vascular endothelial growth factor in retinitis pigmentosa","volume":"49","author":"Salom","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/jop.2010.0044","article-title":"Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa","volume":"26","author":"Salom","year":"2010","journal-title":"J Ocul Pharmacol Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/0002-9394(87)90308-4","article-title":"Grid photocoagulation for macular edema in patients with retinitis pigmentosa","volume":"104","author":"Heckenlively","year":"1987","journal-title":"Am J Ophthalmol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s12325-017-0559-y","article-title":"A review of subthreshold micropulse laser for treatment of macular disorders","volume":"34","author":"Scholz","year":"2017","journal-title":"Adv Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.895208\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T03:38:24Z","timestamp":1652672304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.895208\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":59,"alternative-id":["10.3389\/fmed.2022.895208"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.895208","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"article-number":"895208"}}